Company intelligence / Profile preview

Histograft

Moscow, Russian Federationhistograft.com ↗

Ownership: Private
Development stage: Other

Overview

Histograft’s lead product is a gene‐activated bone substitute approved for clinical use in Russia since 2019. Over 4,000 patients have been treated. The product uses octacalcium phosphate granules coated with plasmid DNA encoding VEGFA to promote angiogenesis and osteoinduction, resulting in improved bone regeneration. Clinical studies are ongoing for additional indications such as degenerative spinal diseases.

Therapeutic areas: NeurologyRheumatologyOther
Modalities: Gene therapyBiologicRecombinant protein (via gene activation)Device (bone substitute material)
Industry: Biotech

Drug pipeline

1 asset

Nucleostim-VEGF

Unknown

Partnerships

Artgen Biotech group investment partnership since mid–2024; no major pharma partnerships disclosed yet.

Beyond the preview

Go deeper on Histograft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histograft.

Explore the full profile